Trial Profile
An Open-Label, Expanded Access Program of Dupilumab in Adult Patients With Bullous Pemphigoid
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 10 Oct 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Bullous pemphigoid
- Focus Expanded access; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 03 Oct 2023 Status changed from suspended to recruiting.
- 21 Jun 2023 New trial record